Description
Potassium canrenoate is a mineralocorticoid/aldosterone antagonist that exhibits cardioprotective, nephroprotective, antihypertensive, and anti-fibrotic activities. In animal models of cardiac ischemia/reperfusion, potassium canrenoate increases phosphorylation of ERK1/2 and Akt, decreasing infarct size in an adenosine receptor-dependent manner. Potassium canrenoate also improves high salt diet-induced renal dysfunction, reversing the effects of hypofiltration. Additionally, potassium canrenoate displays negative inotropic activity at high doses, decreasing heart rate, blood pressure, and ventricular contraction; it also prolongs ventricular repolarization and the refractory period.
References
Schmidt K, Tissier R, Ghaleh B, et al. Cardioprotective effects of mineralocorticoid receptor antagonists at reperfusion. Eur Heart J. 2010 Jul;31(13):1655-62. PMID: 20028693.
Rugale C, Cordaillat M, Mimran A, et al. Time-course reduction of renal function in rats on high sodium intake: acute reversal by potassium canrenoate. Clin Exp Pharmacol Physiol. 2008 Apr;35(4):412-5. PMID: 18307731.
Sugiyama A, Satoh Y, Takahara A, et al. Electropharmacological effects of a spironolactone derivative, potassium canrenoate, assessed in the halothane-anesthetized canine model. J Pharmacol Sci. 2004 Dec;96(4):436-43. PMID: 15599107.
Bos R, Mougenot N, Médiani O, et al. Potassium canrenoate, an aldosterone receptor antagonist, reduces isoprenaline-induced cardiac fibrosis in the rat. J Pharmacol Exp Ther. 2004 Jun;309(3):1160-6. PMID: 14764658.
